Zelquistinel

DB19336InvestigationalSmall molecule

Zelquistinel is under investigation in clinical trial NCT06547489 (GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder).

Chemical structure of Zelquistinel
Mechanism
Curator reviewed
Formula / weight
C15H25N3O5 · 327.381 g/mol (avg)
Also known as
tert-butyl (4S)-2-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-3-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate
Code names
AGN-241751 · GATE-251

Resolves to

Compound
UNII387WYR6N95CAS2151842-64-5ChEMBLCHEMBL5314944
Structure
InChIKeyABAPCYNTEPGBNJ-FTGAXOIBSA-NSMILESC[C@@H](O)[C@H](N1C[C@@]2(CCCN2C(=O)OC(C)(C)C)C1=O)C(N)=O

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Zelquistinel, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In